GA-ENTERSEKT
Entersekt, a global leader in customer and payment authentication solutions for financial fraud prevention, today announced the appointment of Jon Roskill, former Acumatica CEO and Microsoft executive, to its board of directors as part of its continued expansion within North America. In late 2021, Entersekt received significant funding from Accel-KKR, a technology-focused private equity firm, to hire key leadership, launch new branding, and accelerate the expansion within this region.
Jon Roskill joins Entersekt board of directors
A former Corporate Vice President at Microsoft, and CEO of Acumatica, Mr. Roskill brings decades of executive and advisory experience to the Entersekt board as the company continues to introduce advanced customer and payment authentication solutions into the North American market as part of its global expansion. He currently serves as a Senior Advisor with EQT Partners after spending eight years with Acumatica, a cloud ERP provider.
“Jon joins our board of directors at a critical time. Entersekt is at an inflection point in our growth and expansion, particularly in North America,” said Schalk Nolte, CEO of Entersekt. “His vast experience in global go-to-market strategies will bring tremendous value to the company.”
“Entersekt has a tremendous opportunity ahead of it, and I’m excited to be joining at such a pivotal time in its growth” added Roskill. “With proven, patented technologies, excellent leadership, a strong, global customer base and solid financial foundation, I look forward to being a part of Entersekt’s next phase as it establishes itself as a global leader in financial fraud prevention.”
Expansion of the leadership team to drive bullish growth strategy
In addition, Entersekt has also hired new additions to the management team to support and accelerate the speed to market of Context Aware™ Authentication in North America. Key hires include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.
The new team brings with them the following strong leadership experience in the financial services industry:
- Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank and Mastercard.
- Sampath holds a 25-year track record in scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
- Moreno’s experience includes senior marketing leadership roles spanning over 20 years with companies such as Bottomline and Datawatch.
New strategic partnerships as global growth enablers
Many new integrations and partnerships with strategic technology providers are currently underway. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform. Q2 is a leading provider of digital transformation solutions for banking and lending. By supporting pre-integration, these partnerships enable banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology.
Targeting the demand for enhanced security
A recent Forrester Survey of 300 North American fraud prevention decision-makers, reported that all respondents had experienced authentication fraud in the past year. “The investment from Accel-KKR will support the significant market opportunity and demand for the cloud-first, global authentication solutions that Entersekt is known for. We have a strong leadership team in place that will play a critical role in accelerating our business vision to expand and scale into this territory”, concludes Nolte.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom